Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I like $PULM right here right now. $1.30
$PULM Getting closer to the moment Polaris and Arch envisioned years back. And spawned in DARPA Research labs 10+ years ago. Pulmatrix has been around for 10 years -- on the public markets for 5. Having a CEO's prerogative solely focused on G2M opportunities says a lot about where they are in their value-lifecycle. Running on a lean organization which licenses/partners out with leading healthcare companies, pretty sweet business model.
I guarantee you they are well aware of all opportunities.
Additionally -- attention to the pulmonary markets is way up as a result of cv-19 -- creating a fundamentally extremely bullish environment for their exact market space at least the next 5+ years. Think about it -- they are converting already in use worldwide leading oral/capsule pills into inhalers, increasing safety, lowering dosage, and being more effective.
Pulmazole is their first G2M attempt, with Cipla, a 65% respiratory market share in India. They are projecting $3.5-$5B worldwide -- they are not fucking around. The base-product (Itraconazole) is now being researched in clincal Trials in Belgium as of 3/25 for CV-19. FDA has already fast-tracked Pulmazole just 60 days ago.
J&J joined up under their lung cancer initiative. They put $100M cash on the table -- that's 4x their first deal of $22M with cipla.
It's pretty clear what is going on. Exact prices when, a fools errand and missing the point. The stakes are heating up every day. All imo.
PT1: $5
PT2: $10
PT3: $20
PTMania: $50-$100+
g'evening Mick, 02, Billionaires & Readers
$PULM Getting closer to the moment Polaris and Arch envisioned years back. And spawned in DARPA Research labs 10+ years ago. Pulmatrix has been around for 10 years -- on the public markets for 5. Having a CEO's prerogative solely focused on G2M opportunities says a lot about where they are in their value-lifecycle. Running on a lean organization which licenses/partners out with leading healthcare companies, pretty sweet business model.
I guarantee you they are well aware of all opportunities.
Additionally -- attention to the pulmonary markets is way up as a result of cv-19 -- creating a fundamentally extremely bullish environment for their exact market space at least the next 5+ years. Think about it -- they are converting already in use worldwide leading oral/capsule pills into inhalers, increasing safety, lowering dosage, and being more effective.
Pulmazole is their first G2M attempt, with Cipla, a 65% respiratory market share in India. They are projecting $3.5-$5B worldwide -- they are not fucking around. The base-product (Itraconazole) is now being researched in clincal Trials in Belgium as of 3/25 for CV-19. FDA has already fast-tracked Pulmazole just 60 days ago.
J&J joined up under their lung cancer initiative. They put $100M cash on the table -- that's 4x their first deal of $22M with cipla.
It's pretty clear what is going on. Exact prices when, a fools errand and missing the point. The stakes are heating up every day. All imo.
PT1: $5
PT2: $10
PT3: $20
PTMania: $50-$100+
Patent Updates in Europe/US:
https://patents.google.com/patent/EP2611438A1/en
https://patents.google.com/patent/US9233158B2/en
$PULM
Wonder when we are gonna shake the doldrums & the seller.
$MSMY
Their PR said CBD hand sanitizer. Not sure the additional cost of CBD, yet does seem a premium would be not seen as price gauging. Not solely hand sanitizer.
We should be seeing their 10-K soon, no?
$MSMY
Nice summary :)
$PULM
The tweet says "With pre-orders exceeding 50,000 units".
$MSMY
Agreed -- the market hasn't discovered this yet. Perfect timing aligning the company is ready to make their commercial presence known.
Pre-Orders exceed 50,000 units = $300K
$MSMY
Certainly a competitive advantage and great point.
$MSMY
Interesting. $MSMY
Neither -- no buying pressure; low volume market maker methodical stepdown. Frustrating indeed yet we are golden here. Nothing has changed, if anything the macro backdrop has improved for $PULM.
$1.20's and even teens on Friday -- good prices to buy in, will see what they are on the open on Monday.
$PULM
Action could reverse here; ty happy Sunday.
$MSMY
Kinda ridiculous what is going on here.
coffee sips; data drips - 3.13.20
i like $pulm here
Pulmonary Therapeutics Delivery Mechanism Enhancer -- during a time period where there is a heightened awareness of Pulmonary Therapeutics...
Pulmonary Therapeutics Delivery Mechanism Enhancer -- during a time period where there is a heightened awareness of Pulmonary Therapeutics... wait for it...
$PULM
Yes -- financials should be released soon.
$MSMY -- current company in Eclipse strongest actual underlying business that has existed in this shell; these share sells are from legacy business actions / owners, imo.
$MSMY -- needs some life.
Truth oscillates not based upon price.
Yes, yes it is. Connecting patterns is my favorite.
Happy Saturday to you 02
How are you this morning; how is your health recovery going? Good Vibes Only To You.
Sipp'n Coffee; Working With Data; Watching Stocks
$MSMY
G'Morning ole friend :)
Moon Comin' in Leo Today
$PULM <on big watch> -- Respiratory Therapeutics Platform
G'Morning Billionaires & Readers- 3.6.20
Things are Heating Up: $PULM $1.68
Good Morning All -- $PULM $1.68
Welcome, a good time to be in $PULM
Ready to Run -- PT1: $5, PT2: $20
$PULM -- Bullish Divergence from Market - $1.48 -- Something's up?